All Stories

  1. Pulsed Radiofrequency Electromagnetic Fields as Modulators of Inflammation and Wound Healing in Primary Dermal Fibroblasts of Ulcers
  2. Genetic and Molecular Regulations of Neuronal Activity
  3. A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
  4. Effects of Curcumin and Lactoferrin to Inhibit the Growth and Migration of Prostatic Cancer Cells
  5. Proteomic Signature and mRNA Expression in Hippocampus of SAMP8 and SAMR1 Mice during Aging
  6. Wound-Healing Promotion and Anti-Inflammatory Properties of Carvacrol Prodrugs/Hyaluronic Acid Formulations
  7. Improved osteogenic differentiation by extremely low electromagnetic field exposure: possible application for bone engineering
  8. Evaluation of Cell Migration and Cytokines Expression Changes under the Radiofrequency Electromagnetic Field on Wound Healing In Vitro Model
  9. Effects of Probiotic Mixture Supplementation on the Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine in People Living with HIV
  10. In Vitro Wound-Healing Properties of Water-Soluble Terpenoids Loaded on Halloysite Clay
  11. Wound Repair and Extremely Low Frequency-Electromagnetic Field: Insight from In Vitro Study and Potential Clinical Application
  12. nAChRs gene expression and neuroinflammation in APPswe/PS1dE9 transgenic mouse
  13. Pidotimod and Immunological Activation in Individuals Infected with HIV
  14. Assessment of the Vanillin Anti-Inflammatory and Regenerative Potentials in Inflamed Primary Human Gingival Fibroblast
  15. Cholinergic Modulation of the Immune System in Neuroinflammatory Diseases
  16. Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment
  17. Serum microRNA Levels in Diabetes Mellitus
  18. Short ELF-EMF Exposure Targets SIRT1/Nrf2/HO-1 Signaling in THP-1 Cells
  19. Critical Review on the Presence of Phthalates in Food and Evidence of Their Biological Impact
  20. Possible Correlation between Cholinergic System Alterations and Neuro/Inflammation in Multiple Sclerosis
  21. Cholinergic Markers and Cytokines in OSA Patients
  22. Evaluation of Salivary Cytokines and Vitamin D Levels in Periodontopathic Patients
  23. Network between Cytokines, Cortisol and Occupational Stress in Gas and Oilfield Workers
  24. Relationship of Wine Consumption with Alzheimer’s Disease
  25. Saliva, an easily accessible fluid as diagnostic tool and potent stem cell source for Alzheimer’s Disease: Present and future applications
  26. Relationship between Wine Consumption and Alzheimer's Disease
  27. Human Gingival Fibroblasts Exposed to Extremely Low-Frequency Electromagnetic Fields: In Vitro Model of Wound-Healing Improvement
  28. Anti-cancer effects of polyphenols via targeting p53 signaling pathway: updates and future directions
  29. Antiphospholipid Antibodies Overlapping in Isolated Neurological Syndrome and Multiple Sclerosis: Neurobiological Insights and Diagnostic Challenges
  30. Synthesis and biological evaluation of novel analogues of Gly-l-Pro-l-Glu (GPE) as neuroprotective agents
  31. Immune and Inflammatory-Mediated Disorders: From Bench to Bedside
  32. MicroRNA in Sjögren’s Syndrome: Their Potential Roles in Pathogenesis and Diagnosis
  33. Expression Profiling of Cytokine, Cholinergic Markers, and Amyloid-β Deposition in the APPSWE/PS1dE9 Mouse Model of Alzheimer’s Disease Pathology
  34. wound closure may be accelerate by exposure to EMF
  35. Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: implication in peripheral inflammation
  36. The Role of Immunosenescence in Neurodegenerative Diseases
  37. Diabetes Mellitus and Male Aging: Pharmacotherapeutics and Clinical Implications
  38. Neuroinflammation and Alzheimer's Disease: Implications for Microglial Activation
  39. Cholinergic System and Neuroinflammation: Implication in Multiple Sclerosis
  40. Microbiota and Probiotics in Health and HIV Infection
  41. Microbiome and Probiotics inHealth and HIV Infection
  42. Cytokines, Hepatic Fibrosis, and Antiretroviral Therapy Role in Neurocognitive Disorders HIV Related
  43. Dysregulated Homeostasis of Acetylcholine Levels in Immune Cells of RR-Multiple Sclerosis Patients
  44. Effect of Environmental Extremely Low-Frequency Electromagnetic Fields Exposure on Inflammatory Mediators and Serotonin Metabolism in a Human Neuroblastoma Cell Line
  45. Novel NSAID-Derived Drugs for the Potential Treatment of Alzheimer’s Disease
  46. Development of glycine-α-methyl-proline-containing tripeptides with neuroprotective properties
  47. Nicotinic receptor activation negatively modulates pro-inflammatory cytokine production in multiple sclerosis patients
  48. mTOR Activation by PI3K/Akt and ERK Signaling in Short ELF-EMF Exposed Human Keratinocytes
  49. Effect of Probiotic Supplement on Cytokine Levels in HIV-Infected Individuals: A Preliminary Study
  50. Effects of extremely low frequency electromagnetic field (ELF-EMF) on catalase, cytochrome P450 and nitric oxide synthase in erythro-leukemic cells
  51. Experimental model for ELF-EMF exposure: Concern for human health
  52. markers for diagnosis or therapy of neurodegeneration
  53. Neuronal Cellular Responses to Extremely Low Frequency Electromagnetic Field Exposure: Implications Regarding Oxidative Stress and Neurodegeneration
  54. Selective Acetyl- and Butyrylcholinesterase Inhibitors Reduce Amyloid-β Ex Vivo Activation of Peripheral Chemo-cytokines From Alzheimer’s Disease Subjects: Exploring the Cholinergic Anti-inflammatory Pathway
  55. AGE- AND BRAIN AREAS-RELATED EXPRESSION OF CYTOKINES, CHOLINESTERASES, AND NICOTINIC ACETYLCHILINE RECEPTORS
  56. Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
  57. Editorial (Hot Topic:Modulation of Cholinergic System Activity in Neuronal and Non-Neuronal Tissues: Therapeutic Implications)
  58. Synthesis of the Alzheimer Drug Posiphen into its Primary Metabolic Products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their Inhibition of Amyloid Precursor Protein, α -Synuclein Synthesis, Interleukin-1β Release, ...
  59. Cytokines and T cells in atopic dermatitis
  60. Extremely low frequency electromagnetic field and wound healing: implication of cytokines as biological mediators
  61. EMF Exposure Facilitates Wound Healing Events Modulating Cytokines Expression
  62. Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients
  63. Relationship between Inflammatory Mediators, A? Levels and ApoE Genotype in Alzheimer Disease
  64. Activity of matrix metallo proteinases (MMPs) and the tissue inhibitor of MMP (TIMP)-1 in electromagnetic field-exposed THP-1 cells
  65. Job strain in different types of employment affects the immune response
  66. Well-Being at Work and Immune Response
  67. Daily intake of Lactobacillus casei Shirota increases natural killer cell activity in smokers
  68. Effects of Palladium Nanoparticles on the Cytokine Release from Peripheral Blood Mononuclear Cells of Palladium-Sensitized Women
  69. Parkinson’s Disease and Cytokines
  70. Cytokines and Alzheimer’s Disease
  71. Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls
  72. Antiinflammatory effects in THP‐1 cells treated with verbascoside
  73. Multiple Approaches to Analyse the Data for Rat Brain Acetylcholinesterase Inhibition by Cyclophosphamide
  74. The effect of deproteinized bovine bone on osteoblast growth factors and proinflammatory cytokine production
  75. Reale und mediale Produkterfahrungen
  76. Neuroinflammation, AD, and Dementia
  77. Extremely low frequency electromagnetic fields modulate expression of inducible nitric oxide synthase, endothelial nitric oxide synthase and cyclooxygenase-2 in the human keratinocyte cell line HaCat: potential therapeutic effects in wound healing
  78. Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases
  79. Impact of apoE genotype on circulating IL-18 and amyloid beta levels in Alzheimer's disease
  80. Synthesis, Biological Evaluation, and Docking Studies of N-Substituted Acetamidines as Selective Inhibitors of Inducible Nitric Oxide Synthase
  81. Editorial [Hot Topic:Anti-Inflammatory Strategy: Old Ally or New Promise in Therapy (Guest Editor: Marcella Reale)]
  82. Anti-Inflammatory Properties of Acetylcholinesterase Inhibitors Administred in Alzheimers Disease
  83. Peripheral cytokines profile in Parkinson’s disease
  84. A Pathophysiological Role for Selective Alteration of the Cytokine-Chemokine Network – Inflammatory Theory in Alzheimer’s Disease
  85. A Pathophysiological Role for Selective Alteration of the Cytokine–Chemokine Network—Inflammatory Theory in Alzheimer’s Disease
  86. Blood natural killer activity is reduced in men with occupational stress and job insecurity working in a university
  87. Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone®)
  88. Extremely low frequency electromagnetic field enhances human keratinocyte cell growth and decreases proinflammatory chemokine production
  89. Modulation of MCP-1 and iNOS by 50-Hz sinusoidal electromagnetic field
  90. The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients
  91. MCP-1 and MIP-2 expression and production in BB diabetic rat: Effect of chronic hypoxia
  92. Expression and production of two selected beta-chemokines in peripheral blood mononuclear cells from patients with Alzheimer's disease
  93. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1? and interleukin-6 release from lymphocytes of Alzheimer's disease patients
  94. Alzheimer Patients Treated With an AchE Inhibitor Show Higher IL-4 and Lower IL-1?? Levels and Expression in Peripheral Blood Mononuclear Cells
  95. IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors
  96. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines
  97. MCP-1 and MIP-2 response in Trichinella spiralis infected mice treated with 4-deoxypyridoxine (4-DPD)
  98. Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy
  99. Interferon β-1b modulates MCP-1 expression and production in relapsing–remitting multiple sclerosis
  100. Differential production of RANTES and MCP-1 in synovial fluid from the inflamed human knee
  101. Effects of electromagnetic fields produced by radiotelevision broadcasting stations on the immune system of women
  102. Effects of low frequency electromagnetic fields on expression of lymphocyte subsets and production of cytokines of men and women employed in a museum
  103. Differential expression and secretion of RANTES and MCP-1 in activated peripheral blood mononuclear cell cultures of atopic subjects
  104. Endothelial NOS expression and ischemia–reperfusion in isolated working rat heart from hypoxic and hyperoxic conditions
  105. Localization of the e-NOS enzyme in endothelial cells and odontoblasts of healthy human dental pulp
  106. Lymphocyte subpopulations, cytokines and trace elements in asymptomatic atopic women exposed to an urban environment
  107. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-β-1b
  108. Peripheral blood mononuclear cell production of interleukin-8 and IL-8-dependent neutrophil function in hypercholesterolemic patients
  109. Systemic effects of ingested nickel on the immune system of nickel sensitised women
  110. Expression of lymphocyte subpopulations, cytokine serum levels, and blood and urinary trace elements in asymptomatic atopic men exposed to an urban environment
  111. Monocyte Chemotactic Protein-1 Gene Expression and Translation in Formed Granulomatous Calcified Tissue In Vivo
  112. Mast cell recruitment after subcutaneous injection of RANTES in the sole of the rat paw
  113. RANTES and MCP-1 secretion by mononuclear cells of patients with multiple sclerosis
  114. Transforming growth factor β1 induces IL-1 receptor antagonist production and gene expression in rat vascular smooth muscle cells
  115. Serum Levels of Soluble Adhesion Molecules in Chronic Renal Failure and Dialysis Patients
  116. Influence of Interleukin-1 Receptor Antagonist on [3H] Serotonin and Histamine Release by Rat Basophilic Leukemia-2H3 Cells
  117. RANTES is a pro-inflammatory chemokine and chemoattracts basophil cells to extravascular sites
  118. Monocyte chemotactic protein-1 is a proinflammatory chemokine in rat skin injection sites and chemoattracts basophilic granular cells
  119. Massive infiltration of basophilic cells in inflamed tissue after injection of RANTES
  120. Generation of TNFα, IFNγ, IL-6, IL-4 and IL-10 in mouse serum from trichinellosis: effect of the anti-inflammatory compound 4-deoxypyridoxine (4-DPD)
  121. Effect of interleukin-1 receptor antagonist (IL-1RA) on histamine and serotonin release by rat basophilic leukemia cells (RBL-2H3) and peritoneal mast cells
  122. Cysteinyl-leukotriene D4 induced IL-1β expression and release in rat vascular smooth muscle cells
  123. Induction of alkaline phosphatase generation by il-1β and LPS on human neutrophils and macrophages and lack of inhibition by interleukin-1 receptor antagonist
  124. Modulation of rat vascular smooth muscle cell (VSMC) proliferation by cysteinyl leukotriene D4: a role for mediation of interleukin 1
  125. Synergistic Activation of Serum Amyloid a (SAA) by IL-6 and IL-1 in Combination on Human Hep 3B Hepatoma Cell Line. Role of PGE2 and IL-1 Receptor Antagonist
  126. The down-regulation of IL-6-stimulated fibrinogen steady state mRNA and protein levels by human recombinant IL-1 is not PGE2-dependent: Effects of IL-1 receptor antagonist (IL-1RA)
  127. Bacillus Calmette-Gu�rin potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not interleukin-6 in bladder cancer patients
  128. Human recombinant interleukin-1 receptor antagonist (hrIL-1RA) inhibits prostaglandin E2 (PGE2) generation but not alkaline phosphatase activity in in vivo chronic granulomatous tissue induced by KMnO4
  129. Inhibition of Granuloma Formation Induced by Potassium Permanganate in the Mouse by a Specific Human Recombinant Receptor Antagonist for Interleukin-1 (hrIL-1ra)
  130. Blocking the interleukin-1 receptor inhibits leukotriene B4 and prostaglandin E2 generation in human monocyte cultures
  131. Human recombinant interleukin-1 receptor antagonist (hrIL-1ra) enhances the stimulatory effect of interleukin-2 on natural killer cell activity against molt-4 target cells
  132. Inhibition of Interleukin-1 (Alpha and Beta), Interleukin-2 Secretion and Surface Expression of Interleukin-2 Receptor (IL-2R) by a Novel Cytokine Interleukin-1 Receptor Antagonist (IL-lra)
  133. Role of lipoxins A4 and B4 in the generation of arachidonic acid metabolites by rat mast cells and their effect on [3H]serotonin release
  134. Granulocyte-macrophage colony stimulating factor potentiates human polymorphonuclear leukocyte aggregation responses to formyl-methionyl-leucyl-phenylalanine
  135. Inhibition of leukotriene B4(LTB4) by recombinant interleukin-1 receptor antagonist (IL-1RA) on human monocytes
  136. Human recombinant interleukin-1 receptor antagonist inhibits lymphocyte blastogenesis induced by concanavalin A Restorative effect of hrIL-1
  137. Reduced mitogen stimulation of DNA synthesis in human lymphocytes by a human recombinant interleukin-1 receptor antagonist
  138. Adalat
  139. Inhibition of leukotriene B4 in neutrophils by lipoxins A4 and B4
  140. Lipoxins A4 and B4 inhibit leukotriene B4 generation from human neutrophil leukocyte suspensions
  141. Leukocyte inhibitory factor activates human neutrophils and macrophages to release leukotriene B4 and thromboxanes
  142. Lipoxins increase granuloma formation induced by potassium permanganatein vivo
  143. Enhanced natural killer cell activity by proglumetacin, a non-steroidal anti-inflammatory drug
  144. Recombinant Interleukin 1 and Tumor Necrosis Factor Acting in Synergy to Release Thromboxane, 6-KETO-PGF1α, and PGEI2, by Human Neutrophils
  145. Restoration of anti-interleukin-1 depressed natural killer activity by human recombinant interferon α or γ, human recombinant interleukin-2 and indomethacin
  146. Lipoxin A augments release of thromboxane from human polymorphonuclear leukocyte suspensions
  147. Stimulatory effect of hr tumor necrosis factor on TxB2 release by polymorphonuclears and macrophages
  148. In vitro enhanced throboxane B2 release by polymorhonuclear leukocytes and macrophages after treatment with human recombinant interleukin 1
  149. Enhanced thromboxane synthesis and vacuolization in human polymorphonuclear leucocytes induced by human lymphokine containing supernatants
  150. Effect of supernatants from PHA-stimulated and non-stimulated lymphocyte cultures on thromboxane B2 release by polymorphonuclear leukocytesin vitro
  151. A role for Ca2+ in the effect of very low frequency electromagnetic field on the blastogenesis of human lymphocytes
  152. A comparative study of the effects of some non-steroidal anti-inflammatory drugs on prostacyclin productionex vivo and on thromboxane B2 release by polymorphonuclearsin vitro
  153. Reduced mitogenic stimulation of human lymphocytes by extremely low frequency electromagnetic fields
  154. Reale Coulombsysteme
  155. Reale Arbeitsprozessrechnung
  156. Kapitel 4 Reale Konjunkturzyklen und Wachstum
  157. Alzheimer Disease